Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will demonstrate the bioequivalence of metformin after single dose administration of sitagliptin/metformin 50/500 mg fixed dose combination (FDC) tablet and concomitant administration of single doses of sitagliptin 50 mg and metformin 500 mg as individual tablets after consumption of a high-fat meal.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Metformin; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• is in good health

• is a nonsmoker

• is willing to follow all study guidelines

Exclusion Criteria:

• has or has a history of any illness or condition that might confound the results of the study or make participation unsafe for the participant

• is a nursing mother

• is unwilling to consume the required high-fat breakfast